TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01529255

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telbivudine (Standard of Care)
Description: Patients will receive oral telbivudine 600mg, daily for 104 weeks, if HBV DNA breakthrough, add on oral adefovir 10mg daily~Stopping rules:~The participants who achieve HBeAg seroconversion and HBV DNA\<300copies/ml with over 12 months consolidation treatment in EFFORT study will discontinue treatment.~The participants who don't meet the rules above will continue their previous treatment and follow up at the interval of 12 weeks until they finish the 156 weeks therapy or achieve the stopping rules.~Follow up： The participants who stopped treatment will follow up at the interval of 12 weeks for 52 weeks. Of these patients, if they have confirmed virologic relapse during follow-up period, they will be excluded from the trial.
Study: NCT03684811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT-2102
Description: FT-2102 will be supplied as a 150 mg capsule and will be administered per the protocol defined frequency and dose level.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT-2102
Description: FT-2102 will be supplied as a 150 mg capsule and will be administered per the protocol defined frequency and dose level.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT-2102
Description: FT-2102 will be supplied as a 150 mg capsule and will be administered per the protocol defined frequency and dose level.
Study: NCT01215643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisporivir
Description: ALV 200 mg soft gel capsules administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisporivir
Description: ALV 200 mg soft gel capsules administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisporivir
Description: ALV 200 mg soft gel capsules administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisporivir
Description: ALV 200 mg soft gel capsules administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: PEG 180 μg administered via subcutaneous (s.c.) injection once weekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon alfa-2a
Description: PEG 180 μg administered via subcutaneous (s.c.) injection once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: RBV 400 mg (2 x 200 mg tablets) administered orally twice daily (BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: RBV 400 mg (2 x 200 mg tablets) administered orally twice daily (BID)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: RBV 400 mg (2 x 200 mg tablets) administered orally twice daily (BID)
Study: NCT00284557

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group-based behavioral intervention
Description: The group-based behavioral intervention targets eating behaviors, physical activity, and screen time, and is delivered to participating children and their parent/caregiver over the course of 4 weeks. Maintenance sessions occur every 3 months thereafter.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group-based behavioral intervention
Description: The group-based behavioral intervention targets eating behaviors, physical activity, and screen time, and is delivered to participating children and their parent/caregiver over the course of 4 weeks. Maintenance sessions occur every 3 months thereafter.
Study: NCT03723720

Intervention type: DEVICE
Intervention: Colonoscopy
Description: Endoscopic examination of large bowel
Study: NCT04576039

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: saline infusion sonography
Description: Instillation of 10cc of saline infusion in the uterine cavity while performing an ultrasonic evaluation of the uterine cavity and endometrium.
Study: NCT02596958

Intervention type: DRUG
Intervention: Bevacizumab
Description: Six 3-weeks cycle of IV bevacizumab will be administered for approximately 7 months.
Study: NCT03372434

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational Intraocular Lens Device #1: Model ZFR00
Description: IOL replaces the natural lens removed during cataract surgery.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational Intraocular Lens Device #1: Model ZYR00
Description: IOL replaces the natural lens removed during cataract surgery.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TECNIS Multifocal Intraocular Lens: Model ZLB00
Description: IOL replaces the natural lens removed during cataract surgery.
Study: NCT01007929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C-AZD1236
Description: Oral solution 1mg/mL
Study: NCT00082706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (5-FU)
Description: Day: 1 - 5 Dose: 200 mg/m2 IVCI daily x 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Day: 1 - 5 Dose:10 mg/m2 daily x 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Day: 1 - 5 Dose: 20 mg/m2 daily x 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Day: 1 \& 5 Dose: 200 mg/m2 (Two doses only)
Study: NCT03165240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 690517
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 690517
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 690517
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone
Description: Film-coated tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Film-coated tablet
Study: NCT01537159

Intervention type: DEVICE
Intervention: 3 Tesla (3T) Siemens Total imaging matrix (TIM) Trio whole-body system
Description: Each MR scanning session will include the pre-contrast multi-slice T2-weighted MRI with fat-saturation and T1-weighted MRI which are regularly acquired in clinical protocols. Following these acquisitions, high-spatial and temporal-resolution DCE-MRI will be performed. The total duration of a research MR session is expected to be less than 45 min.
Study: NCT02348879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 403
Description: AMG 403 is for treatment of subjects with chronic pain

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: contains no active drug
Study: NCT01530035

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physical training
Description: training

Intervention type: OTHER
Group type: OTHER
Intervention: physical training
Description: training
Study: NCT02421406

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet Behavioral Intervention
Description: A series of 12 multi-media lessons will be accessible to participants on their own computers. The lessons (each of which takes about 15 minutes to complete) are based on the Diabetes Prevention Program (DPP) and Look AHEAD. Participants will be taught to record their weight, the calories and the fat grams in each food item, and their physical activity (in minutes) on a daily basis. At the end of the week, they will submit their self-monitored information to the study website and receive an automated feedback message about their progress to date. The lessons will also present key behavior change strategies such as cognitive restructuring, problem solving and relapse prevention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet Education Intervention
Description: A series of 12 lessons will be accessible to participants on their own computers. Participants will be given information about normal, overweight and obese categories of body mass index, and provided information on the health problems that are associated with being overweight and the benefits of weight loss for treating and preventing such problems. General information about healthy eating will be provided. Participants will be educated about the benefits of increasing their physical activity, and strategies for increasing activity safely.
Study: NCT03297073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol
Description: Paracetamol 1000 mg will be administered 30 minutes before the end of the procedure and then every 6 hours systematically at the following times: 6h / 12h / 18h / 00h.~The analgesic treatment after hepatectomy with paracetamol will be maintained for at least 5 days in all patients in parenteral form

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol
Description: Paracetamol 1000 mg will be administered 30 minutes before the end of the procedure and then every 6 hours systematically at the following times: 6h / 12h / 18h / 00h.~The analgesic treatment after hepatectomy with paracetamol will be maintained for at least 5 days in all patients in parenteral form

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol
Description: Paracetamol 1000 mg will be administered 30 minutes before the end of the procedure and then every 6 hours systematically at the following times: 6h / 12h / 18h / 00h.~The analgesic treatment after hepatectomy with paracetamol will be maintained for at least 5 days in all patients in parenteral form

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hepatic surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hepatic surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hepatic surgery
Study: NCT01707433

Intervention type: OTHER
Intervention: Enzyme testing
Description: Leukocyte activity measurement of Arylsulfatase B and N acetyl galactosamine 6 sulfatase (GALNS)
Study: NCT01073397

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Integral Yoga class (90 minutes per class), Once weekly for 10 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Yoga
Description: Integral Yoga class (90 minutes per class), Once weekly for 10 weeks
Study: NCT04037631

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic device
Description: Diagnostic test
Study: NCT00646321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide/formoterol (Symbicort)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: budesonide
Study: NCT01081704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ustekinumab
Description: Single dose of 45 mg subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ustekinumab
Description: Single dose of 90 mg subcutaneous injection
Study: NCT03114579

Intervention type: DEVICE
Group type: OTHER
Intervention: Intraoperative heart rate measurement (reference method)
Description: Measurement of cardiac output by both monitors: NEXFIN HD and oesophageal doppler, blood pressure measurement by the catheter and NEXFIN HD monitor, and cardiac output and blood pressure measurements after treatment administration (vasoconstrictor or filling)

Intervention type: DEVICE
Group type: OTHER
Intervention: NEXFIN HD
Study: NCT05296824

Intervention type: PROCEDURE
Intervention: Cryoballoon ablation for the treatment of atrial fibrillation
Description: Cryoballoon ablation for the treatment of atrial fibrillation

Intervention type: PROCEDURE
Intervention: Cryoballoon ablation for the treatment of atrial fibrillation
Description: Cryoballoon ablation for the treatment of atrial fibrillation
Study: NCT00052611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Study: NCT01327079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: If the infant has been treated with morphine than substitute for that one study dose 0.1 mg morphine with 0.1 mg methadone, whereas if the infant has been treated with fentanyl substitute for that one study dose 1 μg fentanyl with 0.1 mg methadone.~Administration of inulin:~Inulin will be administered as a glucose 10%-inulin solution containing 25 gr. inulin/L, at an infusion rate of 0.6 mL/kg/h. After 24 h, the inulin clearance will be calculated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: If the infant has been treated with morphine than substitute for that one study dose 0.1 mg morphine with 0.1 mg methadone, whereas if the infant has been treated with fentanyl substitute for that one study dose 1 μg fentanyl with 0.1 mg methadone.~Administration of inulin:~Inulin will be administered as a glucose 10%-inulin solution containing 25 gr. inulin/L, at an infusion rate of 0.6 mL/kg/h. After 24 h, the inulin clearance will be calculated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: If the infant has been treated with morphine than substitute for that one study dose 0.1 mg morphine with 0.1 mg methadone, whereas if the infant has been treated with fentanyl substitute for that one study dose 1 μg fentanyl with 0.1 mg methadone.~Administration of inulin:~Inulin will be administered as a glucose 10%-inulin solution containing 25 gr. inulin/L, at an infusion rate of 0.6 mL/kg/h. After 24 h, the inulin clearance will be calculated.
Study: NCT00963716

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hot biopsy forceps
Description: Endobronchial biopsies taken with the application of an electrocoagulation current by an electrocoagulation-capable biopsy forceps

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cold biopsy forceps
Description: Endobronchial biopsies taken without the application of an electrocoagulation current by an electrocoagulation-capable biopsy forceps
Study: NCT00643786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygène
Description: Flow of gas administrated to the patient between 4 and 15 litre/min during 5 minutes after the end of Kalinox's inhalation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Air Médical
Description: Flow of gas administrated to the patient between 4 and 15 litre/min during 5 minutes after the end of Kalinox's inhalation
Study: NCT00063895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacogenomic studies
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03684811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT-2102
Description: FT-2102 will be supplied as a 150 mg capsule and will be administered per the protocol defined frequency and dose level.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT-2102
Description: FT-2102 will be supplied as a 150 mg capsule and will be administered per the protocol defined frequency and dose level.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine will be administered per the site's standard of care.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be administered per the site's standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine and Cisplatin
Description: Gemcitabine and cisplatin will be administered per the site's standard of care.
Study: NCT03445338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K0706
Description: Study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K0706
Description: Study
Study: NCT00766948

Intervention type: OTHER
Intervention: There is no intervention, this is a biorepository.
Description: There are no interventions in this study.
Study: NCT03445338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K0706
Description: Study
Study: NCT03764189

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: microosteoperforation
Description: small holes made using large round bur
Study: NCT02177305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.02 mcg tiotropium solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.04 mcg tiotropium solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.08 mcg tiotropium solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.16 mcg tiotropium solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.28 mcg tiotropium solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.40 mcg tiotropium solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo solution
Study: NCT01945957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: For Phase I, subjects will be randomized to receive either 24IU (6 sprays) of active oxytocin or 6 sprays of placebo (3 sprays per nostril)~For Phase II, subjects will be randomized to receive either 8 IU or 40 IU of oxytocin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: For Phase I, subjects will be randomized to receive either 24IU (6 sprays) of active oxytocin or 6 sprays of placebo (3 sprays per nostril)~For Phase II, subjects will be randomized to receive either 8 IU or 40 IU of oxytocin.
Study: NCT02902419

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wound dressing removal.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wound dressing removal.
Study: NCT00672412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GPO-Vir Z30 tablet
Description: Tablet consisting of ZDV 30 mg/3TC 15 mg/NVP 28 mg taken orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GPO-Vir Z30 tablet
Description: Tablet consisting of ZDV 30 mg/3TC 15 mg/NVP 28 mg taken orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: Oral suspension containing 10 mg 3TC in each mL. Dosage depends on weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: Oral suspension containing 10 mg 3TC in each mL. Dosage depends on weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine
Description: Oral solution containing 10 mg NVP in each mL. Dosage depends on weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine
Description: Oral solution containing 10 mg NVP in each mL. Dosage depends on weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zidovudine
Description: Oral solution containing 10 mg ZDV in each mL. Dosage depends on weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zidovudine
Description: Oral solution containing 10 mg ZDV in each mL. Dosage depends on weight.
Study: NCT02075229

Intervention type: DEVICE
Intervention: Cochlear implant
Description: A cochlear implant consists of an implantable device that electrically stimulates surviving nerve fibers within the inner ear to produce perceptions of sound in patients with significant sensorineural hearing loss.. The implanted device is controlled by an external sound processor that converts acoustic sound signals into patterns of electrical stimulation that result in sound perception for the user.

Intervention type: DEVICE
Intervention: Cochlear implant
Description: A cochlear implant consists of an implantable device that electrically stimulates surviving nerve fibers within the inner ear to produce perceptions of sound in patients with significant sensorineural hearing loss.. The implanted device is controlled by an external sound processor that converts acoustic sound signals into patterns of electrical stimulation that result in sound perception for the user.
Study: NCT03942627

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Program
Description: The intervention consists of two brief videos (one introducing the NICU portion of the program and one introducing the portion of the program addressing the transition home), as well as a series of mindfulness practices delivered via audio recordings to assist mothers in managing stress during the NICU stay and another series for the transition home.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Infant Health Education Program
Description: The active control condition consists of two brief videos (one introducing the NICU portion of the program and one introducing the portion of the program addressing the transition home), as well as a series of audio recordings providing information on infant health and development for mothers to use during the NICU stay and another series for the transition home.
Study: NCT02555189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT03398681

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferric carboymaltose
Description: Ferric Carboxymaltose solution \[Ferinject® (FCM), Vifor Pharma (Glattbrugg, Switzerland)\]

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Normal saline)
Description: Normal saline (0.9% weight/volume (w/v) NaCl)

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac magnetic resonance
Description: Cardiac magnetic resonance including T2\* and T1-mapping sequences

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Cardiac magnetic resonance
Description: Cardiac magnetic resonance including T2\* and T1-mapping sequences
Study: NCT02000973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: General anesthesia combined with thoracic epidural 1% lidocaine
Study: NCT03438955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omacor
Description: Omacor soft capsule 4000mg for 16days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pritor
Description: Pritor tablet 40mg for 7days